(Reuters) -The U.S. Food and Drug Administration is probing the death of a patient who developed harmful antibodies after taking Takeda Pharmaceuticals' blood disorder therapy, the health regulator said on Friday.
The pediatric patient died about 10 months after starting Takeda's drug Adzynma as a preventive therapy, the agency said.
The child had congenital thrombotic thrombocytopenic purpura (cTTP), an inherited condition that causes blood clots in small vessels and can lead to organ damage.
The FDA said the child developed antibodies that blocked the activity of ADAMTS13, an enzyme critical for blood clotting.
Takeda did not immediately respond to Reuters request for comment.
Adzynma, approved in 2023 as the first therapy for cTTP, replaces the ADAMTS13 protein to help prevent dangerous blood clots.
The agency added it has received multiple postmarketing reports of patients developing neutralizing antibodies to ADAMTS13 after treatment with Adzynma.
(Reporting by Kamal Choudhury in Bengaluru; Editing by Vijay Kishore)
LATEST POSTS
- 1
Watch India launch advanced military satellite on rocket's 1st flight since May 2025 failure - 2Tesla Germany Registrations Quadruple to 9,252 Vehicles in Best March Ever
- 3NASA begins fueling rocket to launch astronauts on the first lunar trip in half a century
- 4Instructions to Help a Friend or family member Determined to have Cellular breakdown in the lungs
- 5Famous SUVs With Low Energy Utilization In 2024
- 10 Moves toward Start Your Own Effective Business
- Man threatens attack on German high-speed train, 12 lightly injured
- Vote In favor of Your Favored Shimmering Water
- Israel kidnaps PIJ terrorist in covert op. in Hamas-controlled Gaza in pursuit of Ran Gvili
- The Main 15 Applications for Efficiency and Association
- the Wild in Style: The Reduced Portage Mustang's Bold Heritage
- Over 60 local leaders push Netanyahu to halt haredi draft bill, warn of social rift
- The Best Games On the planet
- Europe picks companies to help build Argonaut moon lander
